Product Name :MAGEA2 polyclonal antibody
Application_all :WB (1/500 - 1/1000), FC (1/10 - 1/30)
Background :Melanoma-associated antigen 2: Reduces p53/TP53 transactivation function through recruitment of HDAC3 to p53/TP53 transcription sites. Also represses p73/TP73 activity. Proposed to enhance ubiquitin ligase activity of RING-type zinc finger-containing E3 ubiquitin-protein ligases. In vitro enhances ubiquitin ligase activity of TRIM28 and stimulates p53/TP53 ubiquitination by TRIM28 potentially in presence of Ubl-conjugating enzyme UBE2H. Proposed to act through recruitment and/or stabilization of the Ubl-conjugating enzyme (E2) at the E3:substrate complex. May play a role in embryonal development and tumor transformation or aspects of tumor progression. In vitro promotes cell viability in melanoma cell lines. Antigen recognized on a melanoma by autologous cytolytic T-lymphocytes. Negatively regulates acetylation and sumoylation of PML and represses PML-induced p53/TP53 acetylation and activation
Product :1mg/ml in 0.42% Potassium phosphate, 0.87% Sodium chloride, pH 7.3, 30% glycerol, and 0.01% sodium azide.
Purification&Purity :The antibody was purified by immunogen affinity chromatography.
Storage&Stability :Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles.
Specificity :Recognizes endogenous levels of MAGEA2 protein.
Note :For research use only, not for use in diagnostic procedure.
Alternative Name :MAGE2; MAGEA2A; MAGE2; MAGEA2; Melanoma-associated antigen 2; Cancer/testis antigen 1.2; CT1.2; MAGE-2 antigen
Immunogen :A synthetic peptide encompassing a sequence within the N-terminal region of human MAGEA2.
Modification :Unmodification
